araag2/HINT huggingface dataset:
Clinical trial NCT00088478 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: intramuscular olanzapine depot, placebo
SMILES: CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have schizophrenia and be experiencing a psychotic episode

          -  Each patient must have a level of understanding sufficient to complete all tests and
             examinations required by the protocol, and to provide informed consent

          -  Patient must not have participated in a clinical trial of another investigational
             drug, including olanzapine, within 1 month (30 days) prior to the study entry

          -  Female patients must not be pregnant or breast-feeding

          -  Female patients must not be experiencing acute, serious or unstable medical conditions
             other than schizophrenia

        Exclusion Criteria:

          -  Patients who were previously treated with olanzapine and are considered to be
             treatment-resistant to olanzapine, in the opinion of the investigator

          -  One or more seizures without a clear and resolved etiology is exclusionary. However,
             if the patient has had one or more seizures in the past with an identifiable etiology,
             and that etiology has been resolved, the patient may be entered.

          -  Treatment with clozapine within 4 weeks prior to visit 1

          -  DSM-IV or DSM-IV-TR substance (except nicotine and caffeine) dependence within the
             past 30 days

          -  Treatment with remoxipride within 6 months (180 days) prior to visit 1
Clinical trial NCT00276458 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: comparator: atorvastatin, comparator: placebo, comparator: ezetimibe, comparator: placebo.
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN(C)C(=N)NC(N)=N, O[C@@H](CC[C@@H]1[C@H](N(C1=O)C1=CC=C(F)C=C1)C1=CC=C(O)C=C1)C1=CC=C(F)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient with LDL-C >100 mg/dL & on a stable dose of atorvastatin 20 mg

        Exclusion Criteria:

          -  Pregnant or lactating women or intending to become pregnant

          -  Patient with sensitivity or intolerance to ezetimibe or atorvastatin

          -  Patient with diabetes or coronary heart disease
Clinical trial NCT00140543 (phase 3, status: unknown status)
Conditions: diabetes mellitus, type 1, diabetic nephropathy
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44, E10.21, E11.21, E13.21, E08.21, E09.21
Drugs: sirolimus versus mycophenolate mofetil
SMILES: CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female patients, of 18 to 55 years of age, with end-stage, C-peptide-negative,
             Type 1-diabetic nephropathy.

          2. Female patients of childbearing age must have a negative pregnancy test and must agree
             to maintain effective birth control practice throughout the study period (3 years).

          3. Patient must have signed the Patient Informed Consent Form.

          4. Patient must receive a primary simultaneous pancreas/kidney (SPK) cadaveric
             transplant, with either intestinal or bladder and either portal or systemic venous
             drainages.

        Exclusion Criteria:

          1. Patient is pregnant or breastfeeding.

          2. Patient is allergic or intolerant to Mycophenolate Mofetil, Sirolimus, Tacrolimus or
             other macrolides, or any compounds structurally related to these compounds.

          3. Patient has a positive T-cell crossmatch on the most recent serum specimen.

          4. Patient is known for active liver disease or has significant liver disease, defined by
             ASAT and ALAT serum levels greater than 3 times the upper limit of normal.

          5. Patient has malignancy or history of malignancy, with the exception of adequately
             treated localised squamous cell or basal cell carcinoma, without recurrence.

          6. Patient has been included in another clinical trial protocol for any investigational
             drug within 4 weeks prior to randomisation.

          7. Patient has any form of substance abuse, psychiatric disorder or condition, which, in
             the opinion of the investigator, may invalidate communication.

          8. Patient receives a SPK transplant from a living donor, or receives segmental
             pancreatic transplant, or a previous kidney transplant alone.

          9. Pancreatic duct occlusion technique .

         10. Donor is older than 55 years of age.

             -
Clinical trial NCT00393835 (phase 3, status: completed)
Conditions: upper respiratory tract infection
ICD codes: R09.2, A15.7, A15.8, A15.9, J98.9, R06.03, J12.1
Drugs: azithromycin sr
SMILES: [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who were diagnosed Laryngopharyngitis or Tonsillitis or Acute Bacterial
             Rhinosinusitis

        Exclusion Criteria:

          -  Severe underlying disease; patients in which drug clinical evaluation is difficult
             because of confounding diseases.
Clinical trial NCT01381900 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, canagliflozin 100mg, canagliflozin 300mg, metformin, sulphonylurea
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with T2DM with inadequate glycemic control on metformin monotherapy or on
             metformin in combination with an SU at protocol-specified doses and having HbA1c
             >=7.0% and <=10.5% at Week -2 are eligible for enrollment in the study.

        Exclusion Criteria:

          -  History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta
             cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy

          -  Has repeated (ie, 2 or more over a 1-week period) fasting plasma glucose (FPG) and/or
             fasting self-monitored blood glucose (SMBG) measurements >=270 mg/dL (15 mmol/L)
             during the pre-treatment phase, despite reinforcement of diet and exercise counseling

          -  History of a severe hypoglycemic episode within 6 months before screening

          -  History of or current illness considered to be clinically significant by the
             investigator
Clinical trial NCT01300234 (phase 3, status: completed)
Conditions: hepatitis b
ICD codes: B18.0, B18.1, B19.10, B19.11, B17.0, B16.0, B16.1
Drugs: tenofovir disoproxil fumarate (tdf) tablets, adefovir dipivoxil (adv) tablets
SMILES: [H][C@@](C)(CN1C=NC2=C(N)N=CN=C12)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C, CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C(N)N=CN=C12)OCOC(=O)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  HBeAg positive/negative CHB with blood HBVDNA≥10^5 copies/mL and elevated ALT

          -  Nucleoside and nucleotide naïve CHB subjects. Previous lamivudine treatment is allowed
             in less than 10% of the total study population

        Exclusion Criteria:

          -  subjects with hepatocellular carcinoma (HCC) potential or decompensated liver disease

          -  subjects with acute liver disease due to other causes

          -  subjects with medication history of immunosuppressive therapy, immunomodulatory
             therapy, systemic cytotoxic agents, chronic antiviral agents including Chinese herbal
             medicines known to have activity against HBV (e.g., lamivudine, hepatitis B
             immunoglobulin (HBIg)) within the previous 6 months prior to randomisation into this
             study
Clinical trial NCT00413062 (phase 3, status: completed)
Conditions: contraception
ICD codes: Z92.0, Z30.012, Z30.09
Drugs: nomac-e2, drsp-ee
SMILES: [H][C@@]12CC[C@](OC(C)=O)(C(C)=O)[C@@]1(C)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3C(C)=C[C@@]21[H], [H][C@@]12CC[C@@](O)(C#C)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Eligibility criteria:

        Inclusion Criteria:

          -  Sexually active women, at risk for pregnancy and not planning to use condoms;

          -  Women in need for contraception and willing to use an oral contraceptive (OC) for 12
             months (13 cycles);

          -  At least 18 but not older than 50 years of age at the time of screening;

          -  Body mass index >=17 and <=35;

          -  Good physical and mental health;

          -  Willing to give informed consent in writing.

        Exclusion Criteria:

          -  Contraindications for contraceptive steroids

          -  In accordance with the Summary of Product Characteristics (SmPC)/Package Insert of
             DRSP-EE, additional contraindications related to the antimineralocorticoid activity of
             drospirenone (conditions that predispose to hyperkalemia):

          -  Renal insufficiency;

          -  Hepatic dysfunction;

          -  Adrenal insufficiency.

          -  An abnormal cervical smear (i.e.: dysplasia, cervical intraepithelial neoplasia [CIN],
             squamous intraepithelial lesion [SIL], carcinoma in situ, invasive carcinoma) at
             screening;

          -  Clinically relevant abnormal laboratory result at screening as judged by the
             investigator;

          -  Use of an injectable hormonal method of contraception; within 6 months of an injection
             with a 3-month duration, within 4 months of an injection with a 2-month duration,
             within 2 months of an injection with a 1-month duration;

          -  Before spontaneous menstruation has occurred following a delivery or abortion;

          -  Breastfeeding or within 2 months after stopping breastfeeding prior to the start of
             trial medication;

          -  Present use or use within 2 months prior to the start of the trial medication of the
             following drugs: phenytoin, barbiturates, primidone, carbamazepine, oxcarbazepine,
             topiramate, felbamate, rifampicin, nelfinavir, ritonavir, griseofulvin, ketoconazole,
             sex steroids (other than pre- and posttreatment contraceptive method) and herbal
             remedies containing Hypericum perforatum (St John's Wort);

          -  Administration of investigational drugs and/or participation in another clinical trial
             within 2 months prior to the start of the trial medication or during the trial period.

          -  Subjects with a diagnosis of the endometrial biopsy such as hyperplasia, atypical
             hyperplasia, carcinoma or any other abnormality judged clinically relevant by the
             investigator (This is applicable only for the subjects participating in the
             endometrial biopsy substudy).
Clinical trial NCT00399464 (phase 3, status: completed)
Conditions: prostatic hyperplasia
ICD codes: N40.0, N40.1
Drugs: alfuzosin
SMILES: COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N(C)CCCNC(=O)C1CCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Japanese;

          -  Having a symptomatic BPH diagnosed clinically by digital rectal examination and
             ultrasonography within the last 6 months;

          -  Suffering for at least 6 months from lower urinary tract symptoms related to BPH.

        Exclusion Criteria:

          -  Patients with mental disorders or who cannot be relied upon to understand the trial
             requirements and comply with the treatment regiment;

          -  Inpatient;

          -  Patients having participated in a clinical trial within the previous 6-month;

          -  Patients previously treated with SL77.0499-10;

          -  Patients whose I-PSS total score do not meet ≥ 13;

          -  Patients whose urinary peak flow rate (PFR) do not meet 5.0-12.0mL/s for a voided
             volume of at least 150mL;

          -  Patients whose residual urine are > 200mL;

        The investigator will evaluate whether there are other reasons why a patient may not
        participate.
Clinical trial NCT00262990 (phase 3, status: completed)
Conditions: ovarian cancer, fallopian tube cancer, peritoneal neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C57.00, C57.01, C57.02, K65.1, K66.0, N99.4, N73.6, R88.0, Z49.32, Z49.02
Drugs: epo906 (patupilone), doxorubicin
SMILES: [H]\C(=C(\C)[C@]1([H])C[C@]2([H])O[C@]2(C)CCC[C@]([H])(C)[C@]([H])(O)[C@@]([H])(C)C(=O)C(C)(C)[C@@]([H])(O)CC(=O)O1)C1=CSC(C)=N1, COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  Confirmed diagnosis of ovarian, fallopian or peritoneal cancer

          -  No more than three chemotherapy regimens

          -  Most recent regimen must have been platinum based

        Exclusion Criteria:

          -  Have an unresolved bowel obstruction

          -  Have had previous chemotherapy within 3 weeks

          -  Recovering from any surgery for any cause

        Other protocol-defined inclusion/exclusion criteria will apply.
Clinical trial NCT00107081 (phase 3, status: terminated)
Conditions: fever, neutropenia, cancer
ICD codes: A78, A79.0, A93.1, A96.2, R50.82, R50.83, R50.9, D70.4, D70.8, D70.9, P61.5, D70.3, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ciprofloxacin and amoxicillin, i.v. antibiotics
SMILES: OC(=O)C1=CN(C2CC2)C2=CC(N3CCNCC3)=C(F)C=C2C1=O, CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O
Reason stopped: 
    accrual goal for interventional part not achievable
  
Eligibility criteria:

        Inclusion Criteria:

          -  Chemotherapy because of malignancy

          -  Severe neutropenia (absolute neutrophil count ≤ 0.5x10E9/L)

          -  Fever (axillary temperature ≥ 38.5°C once or ≥ 38.0°C during ≥ 2 hours)

          -  Able to swallow oral medication

          -  Written informed consent from patients and/or parents

        Exclusion Criteria:

          -  Status post myeloablative chemotherapy

          -  Diagnosis: acute myeloid leukemia, B-cell acute lymphoblastic leukemia, or B-cell
             Non-Hodgkin lymphoma

          -  Bone marrow involvement by malignancy ≥ 25%

          -  Any comorbidity requiring hospitalization: [1] mean arterial blood pressure < 50 mmHg
             (up to 10 years) / < 60 mmHg (older than 10 years); [2] oxygen saturation < 94% at
             room air; [3] radiologically defined pneumonia; [4] focal bacterial infection; [5]
             blood cultures taken at presentation reported positive at reassessment; [6] need for
             inpatient treatment or observation due to any other reason, as judged by the physician
             in charge

          -  Ever shaking chills

          -  Ever axillary temperature ≥ 39.5°C

          -  Antibacterial treatment before presentation with fever and neutropenia (except for
             prevention against Pneumocystis jiroveci [formerly P. carinii] pneumonia)

          -  Modification or de novo institution of a prophylaxis against P. jiroveci pneumonia

          -  Modification or de novo institution of a therapy with G-CSF or GM-CSF.

          -  Allergy to ciprofloxacin and/or amoxicillin

          -  Serum creatinine level above the upper limit of normal range
Clinical trial NCT00574132 (phase 3, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: bapineuzumab 0.5 mg/kg, placebo control, bapineuzumab 1.0 m/kg
SMILES: CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of probable AD

          -  Age from 50 to less than 89

          -  Mini-Mental Status Exam score of 16-26 inclusive

          -  Brain magnetic resonance imaging (MRI) scan consistent with the diagnosis of AD

          -  Stable doses of medications (cholinesterase inhibitors and memantine allowed)

          -  Caregiver able to attend all clinic visits with patient

        Exclusion Criteria:

          -  Significant neurological disease other than AD

          -  Major psychiatric disorder

          -  Significant systemic illness

          -  History of stroke or seizure, autoimmune disease, myocardial infarction within the
             last 2 years

          -  Smoking greater than 20 cigarettes per day

          -  Anticonvulsants, anti-Parkinson's, anticoagulant, or narcotic medications

          -  Prior treatment experimental immunotherapeutics or vaccines for AD

          -  Women of childbearing potential

          -  Presence of pacemakers, CSF shunts, or foreign metal objects in the eyes, skin or body
Clinical trial NCT00296348 (phase 3, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: tacrolimus, mycophenolate mofetil, daclizumab, steroids
SMILES: COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patient younger than 18 but not younger than 2 years of age

          -  Skeletal age of boys < or = 17, girls < or = 15 years

          -  Patient has end stage kidney disease

          -  Female patient of childbearing potential must have a negative serum pregnancy test
             prior to enrolment and must agree to practice effective birth control during the study
             and 6 weeks thereafter.

          -  The patient, or in case the patient is a minor, the patient's parent(s) or their legal
             representative, has been fully informed and has given written informed consent

        Exclusion Criteria:

          -  Patient has a most recently measured panel reactive antibody (PRA) grade of > or = 50%

          -  Patient is allergic to or intolerant of study medication

          -  Patient and/or donor is known to be HIV positive.

          -  Patient has significant liver disease

          -  Patient with malignancy or history of malignancy

          -  Patient has previously received or is receiving an organ transplant other than kidney.

          -  Patient has been previously enrolled in this study.

          -  Patient with the relapsing and non-diarrhoeal form of haemolytic uraemic syndrome.
Clinical trial NCT00407745 (phase 3, status: completed)
Conditions: neuralgia, spinal cord injuries
ICD codes: G50.0, M54.81, B02.22, M79.2, P15.8, T07.XXXS, P12.89, P13.1, P14.3, T07.XXXA, T07.XXXD
Drugs: placebo, pregabalin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with nerve pain after Spinal cord injury (traumatic, diving, ischemic and
             after removal of benign tumors (except meningioma and fibromas)

          -  Pain has to be chronic(continuous for at least 3 months or intermittent for at least 6
             months

          -  Pain score at least 4 in 4 of 7 days prior to receive treatment.

        Exclusion Criteria:

          -  Pregabalin use in the last 60 days, prior intolerance to pregabalin

          -  Creatinine clearance <60 mL/min.

          -  White blood cell count <2500/mm3; neutrophil count <1500/mm3; platelet count <100 x
             103/ mm3.

          -  Abuse of drugs or alcohol

          -  Unstable medial conditions

          -  Clinically significant abnormal electrocardiogram (ECG).

          -  Presence of severe pain associated with conditions other than spinal cord injury that
             could confound the assessment or self-evaluation of pain due to spinal cord injury.
Clinical trial NCT01099774 (phase 3, status: completed)
Conditions: glaucoma, ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: bimatoprost 0.03% formulation b ophthalmic solution, bimatoprost 0.03% ophthalmic solution
SMILES: CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1, CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patient has ocular hypertension or glaucoma in both eyes

          -  Requires IOP-lowering therapy in each eye

        Exclusion Criteria:

          -  Active or recurrent eye disease that would interfere with interpretation of study data
             in either eye

          -  History of any eye surgery or laser in either eye within 6 months

          -  Required chronic use of other eye medications during the study

          -  Anticipated wearing of contact lenses during the study.

          -  Intermittent use of oral, intramuscular, or intravenous corticosteroids within 21 days
Clinical trial NCT00141453 (phase 3, status: completed)
Conditions: diabetic nephropathy, type 2 diabetes mellitus, proteinuria
ICD codes: E10.21, E11.21, E13.21, E08.21, E09.21, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44, R80.0, R80.8, R80.9, R80.1, R80.2, R80.3, O12.10
Drugs: olmesartan medoxomil, placebo tablets
SMILES: CCCC1=NC(=C(N1CC1=CC=C(C=C1)C1=C(C=CC=C1)C1=NN=NN1)C(O)=O)C(C)(C)O, NC[C@H]1CC[C@@H](CC1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  clinical diagnosis of diabetic nephropathy in patients with type 2 diabetes

          -  albumin-to-creatinine ratio >= 300 mg/g creatinine in first morning urinalysis

          -  serum creatinine between 1.0 and 2.5 mg/dL in women and between 1.2 and 2.5 mg/dL in
             men

        Exclusion Criteria:

          -  type 1 diabetes

          -  non-diabetic nephropathy

          -  history of myocardial infarction

          -  history of cardiac bypass grafting within 3 months

          -  history of percutaneous coronary intervention (PCI) within 6 months

          -  history of carotid artery or peripheral artery revascularization within 6 months

          -  stroke or transient ischemic attack (TIA) within 1 year

          -  unstable angina pectoris

          -  heart failure of NYHA functional classes III or IV

          -  rapid progression of kidney disease within 3 months

          -  severe orthostatic hypotension

          -  serum potassium level =<3.5 mEq(mmol)/L or =>5.5 mEq(mmol)L

          -  history of rapid elevation of the serum creatinine level after starting treatment with
             AII receptor antagonists or ACE inhibitors

          -  poor glycemic control: HbA1c level =>11%

          -  history of myocardial infarction (MI) or coronary artery bypass grafting (CABG) within
             3 months